TruScreen Completes Oversubscribed Placement

NZX/ASX Announcement
25 May 2026
TruScreen Completes Oversubscribed Placement

TruScreen Group Limited (NZX/ASX:TRU) (TruScreen or TRU or Company) is pleased to
advise that further to the announcement of 21 May 2026 “TruScreen announces the opening
of a NZ$2.9m capital raise”, the Company has received firm commitments from both new and
existing investors for an initial placement to institutional and other select investors
("Placement") of approximately 130 million shares at NZ$0.014/A$0.012 per share to raise
approximately NZ$1.82m / A$1.52m before costs.
The Placement was oversubscribed by approximately NZ$820,000. Given that the demand
in the Placement was higher than the Company's available placement capacity, the Company
has agreed with Placement participants to implement a partial deferred settlement for the
Placement as follows:
1. Approximately 110 million shares will be issued under the Company’s existing 15%
placement capacity in a tranche 1 issue on 1 June 2026.
2. Approximately 20 million shares will be issued in tranche 2, subject to receiving an NZX
waiver to permit the later settlement time and shareholder approval at a meeting to be
held on or around 7 July 2026.
3. The Company will issue one free attaching option, for each two (2) new shares issued
under the Placement (including shares issued under both tranche 1 and tranche 2), with
an exercise price NZ$0.014 /A$0.012 and an expiry date two years from the date of
issue, subject to shareholder approval at the shareholder meeting to be held on or around
7 July 2026.
The placement was successfully managed by joint lead managers, S P Corporate Advisory
Pty Limited and Erity Capital Pty Limited.
The renounceable rights issue (see Rights Issue Offer Document lodged with NZX/ASX on
21 May 2026), will open on 29 May 2026 providing eligible shareholders on the record date
of 28 May 2026, the opportunity to take up their entitlement of one (1) share for every five (5)
held at a price of NZ$0.013 /A$0.011. Documents for the Renounceable Rights Issue will be
mailed to shareholders on 29 May 2026.
Tony Ho Chairman commented, “we are pleased with the strong support that we have
received for this placement. In addition to the growth of our distributor business, conversion
of just one of the screening programme submissions under UNITAID’s Global Cervical
Cancer Elimination Call could be transformational for the Company.”

In the event shareholders do not receive application forms for the Renounceable Rights Offer
please contact the share registry MUFG Corporate Markets:
applications.nz@cm.mpms.mufg.com (Please use “TruScreen Rights Offer”) as the subject
of the email, or Telephone +64 9 375 5998 or contact the Company Secretary, contact details
below.

This announcement has been approved by the Board.

Ends


Guy Robertson
Company Secretary
Tel: +61 407 983 270
Email: guyrobertson@truscreen.com



For more information, visit www.truscreen.com or contact:
Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com
Jack Zhang
Media & Investor Relations
jack@sparkplus.org

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures

an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low
level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and processing of
biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel
and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico).
It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has
distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices
marketed and sold in China.
TruScreen technology is recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China
Cervical Cancer Screening Management Guidelines and the COGA Blue Book.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical
List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the Russian guidelines
for the screening of cervical cancer.
In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date,
over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi
Arabia. TruScreen’s vision is “A world without the cervical cancer”.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro
diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV)
nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits
(DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture
technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This
technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening.
DALTONbio’s exceptional, clinically proven products have served tens of millions of lives in the world. They
have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively,
resulting in healthier people everywhere, every day.
To learn more, please visit: www.daltonbio.com/.